Compare Stocks: CHFS, LFWD, NMTC, and CTSO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHFS Nuwellis	$1.08 -4.4%	$4.79	$4.86 ▼ $37.50	$6.52M	1.55	467,323 shs	38,696 shs
CTSO Cytosorbents	$0.37 +0.1%	$0.39	$0.30 ▼ $1.04	$23.25M	1.39	90,371 shs	158,191 shs
LFWD Lifeward	$7.29 -0.4%	$7.48	$4.14 ▼ $10.56	$20.73M	0.38	6,265 shs	9,522 shs
NMTC NeuroOne Medical Technologies	$2.14 +5.4%	$2.39	$1.42 ▼ $6.96	$18.49M	0.61	71,386 shs	58,710 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHFS Nuwellis	0.00%	0.00%	0.00%	0.00%	-79.31%
CTSO Cytosorbents	+0.05%	-1.86%	+2.83%	-19.97%	-59.46%
LFWD Lifeward	-0.41%	-1.35%	+3.40%	+4.44%	-1.22%
NMTC NeuroOne Medical Technologies	+5.42%	+13.83%	+12.63%	-44.70%	-54.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHFS Nuwellis	$1.08 -4.4%	$4.79	$4.86 ▼ $37.50	$6.52M	1.55	467,323 shs	38,696 shs
CTSO Cytosorbents	$0.37 +0.1%	$0.39	$0.30 ▼ $1.04	$23.25M	1.39	90,371 shs	158,191 shs
LFWD Lifeward	$7.29 -0.4%	$7.48	$4.14 ▼ $10.56	$20.73M	0.38	6,265 shs	9,522 shs
NMTC NeuroOne Medical Technologies	$2.14 +5.4%	$2.39	$1.42 ▼ $6.96	$18.49M	0.61	71,386 shs	58,710 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHFS Nuwellis	0.00%	0.00%	0.00%	0.00%	-79.31%
CTSO Cytosorbents	+0.05%	-1.86%	+2.83%	-19.97%	-59.46%
LFWD Lifeward	-0.41%	-1.35%	+3.40%	+4.44%	-1.22%
NMTC NeuroOne Medical Technologies	+5.42%	+13.83%	+12.63%	-44.70%	-54.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHFS Nuwellis	0.00	N/A	N/A	N/A
CTSO Cytosorbents	2.00	Hold	$5.38	1,351.92% Upside
LFWD Lifeward	2.25	Hold	$10.00	37.17% Upside
NMTC NeuroOne Medical Technologies	2.40	Hold	$7.33	242.68% Upside

Current Analyst Ratings Breakdown

Latest CHFS, LFWD, NMTC, and CTSO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	NMTC NeuroOne Medical Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	LFWD Lifeward	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	LFWD Lifeward	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/18/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	NMTC NeuroOne Medical Technologies	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$13.00 ➝ $5.00
8/3/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	NMTC NeuroOne Medical Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/27/2026	LFWD Lifeward	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	CTSO Cytosorbents	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/3/2026	LFWD Lifeward	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHFS Nuwellis	$5.51M	1.18	N/A	N/A	$12.79 per share	0.08
CTSO Cytosorbents	$37.06M	0.63	N/A	N/A	$0.09 per share	4.11
LFWD Lifeward	$22.03M	0.94	N/A	N/A	$5.52 per share	1.32
NMTC NeuroOne Medical Technologies	$12.10M	1.61	N/A	N/A	$0.85 per share	2.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHFS Nuwellis	-$18.11M	-$279.28	N/A	N/A	N/A	-254.26%	-173.61%	-131.01%	N/A
CTSO Cytosorbents	-$8.20M	-$0.29	N/A	N/A	N/A	-48.94%	-431.65%	-41.94%	11/12/2026 (Estimated)
LFWD Lifeward	-$19.91M	-$16.82	N/A	N/A	N/A	-141.28%	-235.86%	-81.72%	11/13/2026 (Estimated)
NMTC NeuroOne Medical Technologies	-$3.61M	-$0.95	N/A	N/A	N/A	-71.50%	-128.12%	-86.34%	N/A

Latest CHFS, LFWD, NMTC, and CTSO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2026	Q2 2026	LFWD Lifeward	-$1.39	-$1.46	-$0.07	-$4.12	$6.53 million	$6.62 million
8/13/2026	Q3 2026	NMTC NeuroOne Medical Technologies	-$0.21	-$0.28	-$0.07	-$0.28	$2.17 million	$1.97 million
8/6/2026	Q2 2026	CTSO Cytosorbents	-$0.04	-$0.07	-$0.03	-$0.07	$9.39 million	$9.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHFS Nuwellis	N/A	N/A	N/A	N/A	N/A
CTSO Cytosorbents	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
NMTC NeuroOne Medical Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHFS Nuwellis	N/A	6.87	5.97
CTSO Cytosorbents	4.70	0.66	0.50
LFWD Lifeward	0.70	2.33	1.77
NMTC NeuroOne Medical Technologies	N/A	2.84	1.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHFS Nuwellis	65.06%
CTSO Cytosorbents	32.87%
LFWD Lifeward	26.76%
NMTC NeuroOne Medical Technologies	16.07%

Insider Ownership

Company	Insider Ownership
CHFS Nuwellis	0.60%
CTSO Cytosorbents	7.80%
LFWD Lifeward	1.50%
NMTC NeuroOne Medical Technologies	11.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHFS Nuwellis	66	6.04 million	N/A	Not Optionable
CTSO Cytosorbents	220	62.84 million	57.94 million	Optionable
LFWD Lifeward	60	2.83 million	2.79 million	Optionable
NMTC NeuroOne Medical Technologies	20	9.11 million	8.03 million	Optionable

CHFS, LFWD, NMTC, and CTSO Headlines

Recent News About These Companies

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification

August 11, 2026 | finance.yahoo.com

NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED(TM) Platform

July 30, 2026 | finance.yahoo.com

NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians

July 28, 2026 | finance.yahoo.com

NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial

July 16, 2026 | finance.yahoo.com

NeuroOne Medical Technologies (NASDAQ:NMTC) Director Mark Christianson Sells 10,000 Shares

July 3, 2026 | insidertrades.com

NeuroOne(R) Added to Russell Microcap(R) Index

June 29, 2026 | finance.yahoo.com

NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 25, 2026 | finance.yahoo.com

NeuroOne(R) Announces Preliminary Inclusion in Russell Microcap(R) Index

June 16, 2026 | finance.yahoo.com

NeuroOne Expands At-The-Market Equity Offering Capacity

June 12, 2026 | tipranks.com

NeuroOne(R) to Present at the Planet MicroCap Las Vegas 2026 Conference Wednesday, June 17, 2026 at 12:00 p.m. Pacific Time

June 8, 2026 | finance.yahoo.com

NeuroOne(R) to Present at the 2026 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting on May 31, 2026

May 28, 2026 | finance.yahoo.com

NeuroOne(R) Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026

May 22, 2026 | finance.yahoo.com

NeuroOne Medical Technologies Corp (NMTC) Q2 2026 Earnings Report Preview: What to Look For

May 11, 2026 | finance.yahoo.com

NeuroOne(R) Regains Compliance With Nasdaq Listing Requirement

May 4, 2026 | finance.yahoo.com

NeuroOne Appoints New CFO Amid Planned Leadership Transition

May 3, 2026 | theglobeandmail.com

NeuroOne(R) Announces Chief Financial Officer Succession Plan

April 30, 2026 | finance.yahoo.com

NeuroOne Medical Technologies (NMTC) price target increased by 500.01% to 12.44

April 29, 2026 | msn.com

NeuroOne(R) Advances Brain Drug Delivery Platform Through Collaboration With University of Minnesota

April 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHFS, LFWD, NMTC, and CTSO Company Descriptions

Nuwellis NASDAQ:CHFS

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Cytosorbents NASDAQ:CTSO

$0.37 +0.00 (+0.05%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$0.37 0.00 (-0.05%)

As of 08/24/2026 05:22 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Lifeward NASDAQ:LFWD

$7.29 -0.03 (-0.41%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$7.36 +0.07 (+0.89%)

As of 08/24/2026 04:10 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

NeuroOne Medical Technologies NASDAQ:NMTC

$2.14 +0.11 (+5.42%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$2.18 +0.04 (+2.10%)

As of 08/24/2026 04:41 PM Eastern

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHFS, LFWD, NMTC, and CTSO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHFS, LFWD, NMTC, and CTSO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHFS, LFWD, NMTC, and CTSO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHFS, LFWD, NMTC, and CTSO Company Descriptions

Nuwellis NASDAQ:CHFS

Cytosorbents NASDAQ:CTSO

Lifeward NASDAQ:LFWD

NeuroOne Medical Technologies NASDAQ:NMTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHFS, LFWD, NMTC, and CTSO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHFS, LFWD, NMTC, and CTSO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHFS, LFWD, NMTC, and CTSO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHFS, LFWD, NMTC, and CTSO Company Descriptions

Nuwellis NASDAQ:CHFS

Cytosorbents NASDAQ:CTSO

Lifeward NASDAQ:LFWD

NeuroOne Medical Technologies NASDAQ:NMTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools